<DOC>
	<DOC>NCT01272908</DOC>
	<brief_summary>This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.</brief_summary>
	<brief_title>A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients, 1880 years of age Moderate to severe active rheumatoid arthritis Inadequate response to a single previous or current treatment with an antiTNF agent Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks Previous treatment with MabThera Use of an antiTNF agent within past 8 weeks (4 in the case of etanercept) Concurrent treatment with any Disease Modifying AntiRheumatic Drug (DMARD) other than methotrexate Active infection, or history of serious or chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>